The first patient has been dosed in the resumed Phase 2a clinical trial of montelukast for mild to moderate Alzheimer’s disease. IntelGenx, the company running the study known as BUENA (NCT03402503), suspended the trial in late 2020 due to increased concern regarding the COVID-19 pandemic. “Resumption of patient dosing after a COVID-related interruption of the study of over one year is a significant milestone for this novel drug repurposing program,” Horst Zerbe, PhD, CEO of…
You must be logged in to read/download the full post.
The post First Patient Dosed in Resumed Trial of Montelukast for Alzheimer’s appeared first on BioNewsFeeds.